Re: Elafin License Agreement
EXHIBIT 10.19
Prof. Dr. med. Xxxxxx Xxxxxx
Xxxxxxxx 00
D-24105 Kiel
Germany
Kiel, on February 6, 2012
Proteo, Inc.
Att: Chief Executive Officer
Xx. Xxxxx Xxxxxxxx
0000 Xxxxxxxx Xxxxxx Xxxxx
Irvine, CA 92612
USA
Dear Xx. Xxxxxxxx.
This is to confirm certain agreements and understandings reached between me and Proteo, Inc. in December 2011 based on the following background:
Pursuant to the provisions of the license agreement between Proteo, Inc. (hereinafter “Licensee“) and myself (hereinafter “Licensor“, Licensee and Licensor collectively the “Parties”) dated December 30th, 2000 as amended on December 23rd, 2008 (hereinafter the “License Agreement“), Licensee promised to pay certain amounts to Licensor. In December 2007, December 2008 and February 2012, Licensee paid to Licensor 30,000 Euros per year and no other payments were made under the License Agreement to Licensor as of February 6, 2012. I herewith confirm that based on the foregoing we have agreed on the following in December 2011:
|
1.
|
The Parties herewith agree that Licensor defers to April 15, 2013 the instalment payable by Licensee in the amount of 60,000 Euros, which otherwise would be due on December 31st, 2011 (hereinafter the “Deferral”).
|
|
2.
|
Neither the waiver nor the Deferral under Section 1 hereof, would constitute a waiver of or estoppel to Licensor‘s rights to already existing or future payment obligations under the License Agreement.
|
Please confirm by respective countersignature that you are in agreement with this letter and with this confirmation of our agreement from December 2011.
Kind regards,
/s/ Xxxxxx Xxxxxx
Prof. Dr. med. Xxxxxx Xxxxxx
We agree to the foregoing
Proteo, Inc., on 02/06/2012
/s/ Xxxxx Xxxxxxxx
Xxxxx Xxxxxxxx, Chief Executive Officer
